Walleye Capital’s Sonnet BioTherapeutics SONN Stock Holding History

Walleye Capital’s Portfolio SONN Stock Details SONN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-9,458	Closed	-$599K	–	4854
2023 Q1	$599K	Buy	+9,458	New	+$1.53M	0.01%	1562

Other funds holding SONN

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

MCG

McCollum Christoferson Group Amherst, New York $341M AUM 15.01% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Walleye Capital's SONN Position: Q2 2023 in Review

Walleye Capital sold out of Sonnet BioTherapeutics (SONN) in Q2 2023, closing a stake of 9,458 shares — an estimated $599K sold.

Walleye Capital first reported a position in SONN in Q1 2023 and held it in 1 quarter. The position peaked at $599K in Q1 2023. 21 funds tracked by Wall St. Rank hold SONN as of Q2 2023.

Walleye Capital reported no remaining Sonnet BioTherapeutics position as of Q2 2023 after selling out during the quarter.
Walleye Capital sold 9,458 Sonnet BioTherapeutics shares in Q2 2023, an estimated $599K.
Walleye Capital first reported a position in Sonnet BioTherapeutics in Q1 2023 and held it in 1 quarter.
Walleye Capital's Sonnet BioTherapeutics position peaked at $599K in Q1 2023.
21 funds tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q2 2023.

Based on Walleye Capital's 13F filing for Q2 2023, filed 14 Aug 2023.